Cargando…

A Variant Carbapenem Inactivation Method (CIM) for Acinetobacter baumannii Group with Shortened Time-to-Result: rCIM-A

Carbapenem-resistant Acinetobacter baumannii group organisms (CRAB) are challenging because the choice between targeted, new antibiotic drug options and hygiene measures should be guided by a timely identification of resistance mechanisms. In CRAB, acquired class-D carbapenemases (CHDLs) are active...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitteregger, Dieter, Wessely, Julian, Barišić, Ivan, Bedenić, Branka, Kosak, Dieter, Kundi, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024794/
https://www.ncbi.nlm.nih.gov/pubmed/35456157
http://dx.doi.org/10.3390/pathogens11040482
_version_ 1784690694571425792
author Mitteregger, Dieter
Wessely, Julian
Barišić, Ivan
Bedenić, Branka
Kosak, Dieter
Kundi, Michael
author_facet Mitteregger, Dieter
Wessely, Julian
Barišić, Ivan
Bedenić, Branka
Kosak, Dieter
Kundi, Michael
author_sort Mitteregger, Dieter
collection PubMed
description Carbapenem-resistant Acinetobacter baumannii group organisms (CRAB) are challenging because the choice between targeted, new antibiotic drug options and hygiene measures should be guided by a timely identification of resistance mechanisms. In CRAB, acquired class-D carbapenemases (CHDLs) are active against meropenem and imipenem. If PCR methods are not the first choice, phenotypic methods have to be implemented. While promising, the carbapenemase inactivation method (CIM) using meropenem-hydrolysis is, however, hampered by poor performance or overly long time-to-result. We developed a rapid CIM (rCIM-A) with good performance using ertapenem, imipenem, and meropenem disks, 2-h permeabilization and incubation with the test strain in trypticase soy broth, and a read-out of residual carbapenem activity after 6 h, and optionally after 16–18 h. Using clinical isolates and type-strains of Acinetobacter (n = 67) not harboring carbapenemases (n = 28) or harboring acquired carbapenemases (n = 39), the sensitivity of detection was 97.4% with the imipenem disk after 6 h at a specificity of 92.9%. If the inhibition zone around the ertapenem disk at 6 h was 6 or ≤26 mm at 16–18 h, or ≤25.5 mm for meropenem, the specificity was 100%. Because of the high negative predictive value, the rCIM-A seems particularly appropriate in areas of lower CRAB-frequency.
format Online
Article
Text
id pubmed-9024794
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90247942022-04-23 A Variant Carbapenem Inactivation Method (CIM) for Acinetobacter baumannii Group with Shortened Time-to-Result: rCIM-A Mitteregger, Dieter Wessely, Julian Barišić, Ivan Bedenić, Branka Kosak, Dieter Kundi, Michael Pathogens Article Carbapenem-resistant Acinetobacter baumannii group organisms (CRAB) are challenging because the choice between targeted, new antibiotic drug options and hygiene measures should be guided by a timely identification of resistance mechanisms. In CRAB, acquired class-D carbapenemases (CHDLs) are active against meropenem and imipenem. If PCR methods are not the first choice, phenotypic methods have to be implemented. While promising, the carbapenemase inactivation method (CIM) using meropenem-hydrolysis is, however, hampered by poor performance or overly long time-to-result. We developed a rapid CIM (rCIM-A) with good performance using ertapenem, imipenem, and meropenem disks, 2-h permeabilization and incubation with the test strain in trypticase soy broth, and a read-out of residual carbapenem activity after 6 h, and optionally after 16–18 h. Using clinical isolates and type-strains of Acinetobacter (n = 67) not harboring carbapenemases (n = 28) or harboring acquired carbapenemases (n = 39), the sensitivity of detection was 97.4% with the imipenem disk after 6 h at a specificity of 92.9%. If the inhibition zone around the ertapenem disk at 6 h was 6 or ≤26 mm at 16–18 h, or ≤25.5 mm for meropenem, the specificity was 100%. Because of the high negative predictive value, the rCIM-A seems particularly appropriate in areas of lower CRAB-frequency. MDPI 2022-04-18 /pmc/articles/PMC9024794/ /pubmed/35456157 http://dx.doi.org/10.3390/pathogens11040482 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mitteregger, Dieter
Wessely, Julian
Barišić, Ivan
Bedenić, Branka
Kosak, Dieter
Kundi, Michael
A Variant Carbapenem Inactivation Method (CIM) for Acinetobacter baumannii Group with Shortened Time-to-Result: rCIM-A
title A Variant Carbapenem Inactivation Method (CIM) for Acinetobacter baumannii Group with Shortened Time-to-Result: rCIM-A
title_full A Variant Carbapenem Inactivation Method (CIM) for Acinetobacter baumannii Group with Shortened Time-to-Result: rCIM-A
title_fullStr A Variant Carbapenem Inactivation Method (CIM) for Acinetobacter baumannii Group with Shortened Time-to-Result: rCIM-A
title_full_unstemmed A Variant Carbapenem Inactivation Method (CIM) for Acinetobacter baumannii Group with Shortened Time-to-Result: rCIM-A
title_short A Variant Carbapenem Inactivation Method (CIM) for Acinetobacter baumannii Group with Shortened Time-to-Result: rCIM-A
title_sort variant carbapenem inactivation method (cim) for acinetobacter baumannii group with shortened time-to-result: rcim-a
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024794/
https://www.ncbi.nlm.nih.gov/pubmed/35456157
http://dx.doi.org/10.3390/pathogens11040482
work_keys_str_mv AT mittereggerdieter avariantcarbapeneminactivationmethodcimforacinetobacterbaumanniigroupwithshortenedtimetoresultrcima
AT wesselyjulian avariantcarbapeneminactivationmethodcimforacinetobacterbaumanniigroupwithshortenedtimetoresultrcima
AT barisicivan avariantcarbapeneminactivationmethodcimforacinetobacterbaumanniigroupwithshortenedtimetoresultrcima
AT bedenicbranka avariantcarbapeneminactivationmethodcimforacinetobacterbaumanniigroupwithshortenedtimetoresultrcima
AT kosakdieter avariantcarbapeneminactivationmethodcimforacinetobacterbaumanniigroupwithshortenedtimetoresultrcima
AT kundimichael avariantcarbapeneminactivationmethodcimforacinetobacterbaumanniigroupwithshortenedtimetoresultrcima
AT mittereggerdieter variantcarbapeneminactivationmethodcimforacinetobacterbaumanniigroupwithshortenedtimetoresultrcima
AT wesselyjulian variantcarbapeneminactivationmethodcimforacinetobacterbaumanniigroupwithshortenedtimetoresultrcima
AT barisicivan variantcarbapeneminactivationmethodcimforacinetobacterbaumanniigroupwithshortenedtimetoresultrcima
AT bedenicbranka variantcarbapeneminactivationmethodcimforacinetobacterbaumanniigroupwithshortenedtimetoresultrcima
AT kosakdieter variantcarbapeneminactivationmethodcimforacinetobacterbaumanniigroupwithshortenedtimetoresultrcima
AT kundimichael variantcarbapeneminactivationmethodcimforacinetobacterbaumanniigroupwithshortenedtimetoresultrcima